DSpace Collection:http://hdl.handle.net/20.500.12188/1772024-03-29T13:23:55Z2024-03-29T13:23:55ZStatic and dynamic quantum mechanical methods for exact interpretation of Infrared Multiple Photon Dissociation Spectra: current state and development perspectivesAchevski, BlagojTonikj ribarska, JasminaPetkovska, RumenkaPejov, Ljupcohttp://hdl.handle.net/20.500.12188/254062023-09-14T12:11:48Z2022-12-31T00:00:00ZTitle: Static and dynamic quantum mechanical methods for exact interpretation of Infrared Multiple Photon Dissociation Spectra: current state and development perspectives
Authors: Achevski, Blagoj; Tonikj ribarska, Jasmina; Petkovska, Rumenka; Pejov, Ljupco
Description: Conference abstract2022-12-31T00:00:00ZMDM2309 (rs2279744) polymorphisms and risk for HPV persistence and cervical intraepithelial lesions and cervical cancer development in Macedonian womenSotirijaDuvlis, Drage Dabeski, Ljube Ivkovski, Marija Hiljadnikova-Bajro, Dijana Plaseska Karanfilskahttp://hdl.handle.net/20.500.12188/252982022-12-28T13:27:19Z2018-01-01T00:00:00ZTitle: MDM2309 (rs2279744) polymorphisms and risk for HPV persistence and cervical intraepithelial lesions and cervical cancer development in Macedonian women
Authors: SotirijaDuvlis, Drage Dabeski, Ljube Ivkovski, Marija Hiljadnikova-Bajro, Dijana Plaseska Karanfilska2018-01-01T00:00:00ZBiomolecular laboratory markers in cancer managementHiljadnikova-Bajro, Marijahttp://hdl.handle.net/20.500.12188/250802023-09-14T12:09:41Z2017-01-01T00:00:00ZTitle: Biomolecular laboratory markers in cancer management
Authors: Hiljadnikova-Bajro, Marija
Abstract: The laboratory analysis is a compulsory supplement to clinical evaluation in making decisions upon diagnosis and treatment of cancer, one of the leading causes of death worldwide. The traditional biochemical laboratory protocols employed in diagnosis, prognosis and monitoring of malignant diseases include testing of soluble macromolecules as tumor markers and certain common parameters corresponding to the specific type of malignancy, but their limited reliability urges the necessity of identifying new biomarkers with higher specificity, sensitivity and predictability. Biomolecular/genetic testing is an emerging field within the scope of laboratory analysis with high clinical potential based on the assumption that revealing the genetic profile unique to each individual cancer may help predict the prognosis and select an appropriate treatment to target
the changes in the specific tumor.
This work reviews the currently available genomic laboratory tests and highlights their clinical and scientific relevance. Implication of aberrant transcripts BCR-ABL and PML-RAR for the management of leukemias, detection of genetic and epigenetic aberrations associated with familial cancer syndromes (MMR gene defects in Lynch Syndrome), pharmacogenetic assays for HER2, EGFR, ALK, KRAS, BRAF, UGT1A1 testing for selection of appropriate most efficient and least toxic treatment of particular cancer types will be addressed, along with novel, recently identified markers with anticipated clinical impact.
The rapid development of high throughput technologies shifting singleplex towards multiplex testing, such as the next generation sequencing paired with bioinformatics which enable fast and affordable sequencing of the entire genome of an individual, will inevitably empower accelerated establishment of new biomolecular markers associated with the process of cancer initiation and progression. A comparative overview of the contemporary methodologies will be presented in the lecture. Multidisciplinary efforts should be made to implement the benefits from the technological advancement in the scientific process of new biomarker identification and translation of the research results into clinical practice, in order to provide best treatment for cancer patients in accordance with the principles of the precision medicine.2017-01-01T00:00:00ZPharmacogenetic testing in optimization of treatment with statinsHiljadnikova-Bajro, Marijahttp://hdl.handle.net/20.500.12188/250782023-09-14T12:09:21Z2018-10-01T00:00:00ZTitle: Pharmacogenetic testing in optimization of treatment with statins
Authors: Hiljadnikova-Bajro, Marija
Abstract: Statins are a class of drugs that have been widely prescribed nowadays for treating hypercholesterolemia and thus prevent the risk of atherosclerotic cardiovascular events and consecutive mortality. Unfortunate ly, the patient’s compliance with treatment is frequently compromised by the high incidence of adverse effects including hepatotoxicity, myotoxicity, increased risk for diabetes mellitus etc. The expansion of the precision medicine concept in pharmacology has introduced pharmacogenetic testing as a potential predictive strategy in statins pharmacotherapy.
A thorough literature survey was performed using the PubMed database on the published data in English language in the period 2000-2017, regarding genotype-phenotype associations in statin-induced toxicity, identifying a growing body of evidence supporting the need for pharmacogenetic approach in treatment with statins. Polymorphisms in the genes coding for the CYP450 enzymes: CYP2D6, DYP2D9, CYP3A4 and drug transporter genes like ABCB1, ABCG2 and SLCO1B1 appear to be responsible for the variable re sponse and toxicity of statins. But, many studies highlight the importance of drug interactions and epi genetics in modifying the response towards this class of drugs metabolized via pathways shared by the majority of pharmaceutical agents.
With the rapid development of molecular techniques accompanied by a dramatic cost reduction in genetic testing, it can be easily anticipated that pharmacogenetic patient profiling will soon become standard of care in designing the optimal statin treatment either as a monotherapy or in combination with other phar maceuticals.2018-10-01T00:00:00Z